Pimavanserin is safe and does not worsen motor symptoms or cause sedation
FRIDAY, Nov. 1 (HealthDay News) -- An investigational drug is safe and effective in the treatment of Parkinson's disease psychosis, according to a study published online Nov. 1 in The Lancet.
Jeffrey Cummings, M.D., from the Cleveland Clinic, and colleagues randomly assigned 199 patients with Parkinson's disease psychosis to placebo or pimavanserin, a selective serotonin 5-HT2A inverse agonist, for six weeks. Patients were not allowed to take antipsychotic drugs during the study.
The researchers found that pimavanserin treatment had significant antipsychotic benefits compared with placebo, as assessed by the Parkinson's disease-adapted scale for assessment of positive symptoms (5.79 versus 2.73 decrease in scores). More patients in the pimavanserin group discontinued due to an adverse event (10 versus two patients). Pimavanserin was well tolerated, with no exacerbation of motor disability, sedation, or significant safety concerns.
"Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist," Cummings and colleagues conclude.
Several authors disclosed financial ties to pharmaceutical companies, including ACADIA, which manufactures pimavanserin and funded the study.
Abstract (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62106-6/abstract )Full Text (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62106-6/fulltext )Editorial (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62157-1/fulltext )